Proteogenomic Biomarker Panels in a Serial Blood & Urine Monitoring Study of Kidney Transplant Recipients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

307 participants

Study Classification

OBSERVATIONAL

Study Start Date

2011-03-31

Study Completion Date

2016-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

There is a need to develop blood and/or urine tests that will help to detect early signs of rejection in people who have had kidney transplant. Researchers will examine blood, urine, and tissue samples and try to identify genetic markers for certain conditions like rejection, response to therapy, and scarring of the kidney. By studying gene patterns, researchers hope to be able to diagnose these conditions earlier and improve kidney survival.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Correlation of Molecular Biomarkers With Biopsy Findings and Outcomes in Renal Transplant Recipients

NCT02463253

Delayed Graft Function

COMPLETED

New Urine and Blood Markers for Acute Kidney Injury in Liver Transplant Patients

NCT00855127

Renal Insufficiency, Acute

WITHDRAWN

Urine Testing to Detect Kidney Transplant Rejection

NCT00337220

Kidney Transplantation Kidney Disease Kidney Failure, Chronic

COMPLETED

Non Invasive Blood Test To Diagnose Acute Rejection After Kidney Transplantation

NCT02424227

Kidney Transplant Recipients

UNKNOWN

Metabolite Biomarkers Related to Acute Rejection in Kidney Transplantation

NCT03134625

Kidney Transplantation Rejection Acute Renal

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Kidney transplantation is a good treatment option for people with kidney disease. However, there is still much to learn about how to best care for the transplanted kidney and keep it working for a long time. One field of interest is how one's cellular make-up might affect the body's immune response (body's natural defense system to illness and foreign things) to a kidney transplant. Cellular tests, like gene expression, help doctors to study a person's cellular traits. Gene expression is when information found in one's DNA is translated into RNA and eventually proteins. These components are present in each of the body's cells. In this study, researchers are trying to learn if certain changes in the RNA and proteins found in blood, urine, or transplant biopsy tissue can detect rejection before injury can occur or become too severe. The blood and urine tests will look for patterns in one's DNA (called genetic markers).

This study will follow subjects for 2 years after transplant. There will be a total of 12 study visits with additional study visits if rejection occurs. The study requires additional samples of blood, urine, and tissue to be collected during routine clinical visits and biopsies (a procedure to remove and examine a small piece of kidney tissue).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Kidney Transplant Kidney Transplantation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subjects undergoing primary or subsequent deceased-donor or living donor kidney transplantation
* Subject and/or parent guardian must be able to understand and provide informed consent
* Female subjects of childbearing potential must have a negative pregnancy test within 6 weeks of study entry.

Exclusion Criteria

* Need for combined organ transplantation with an extra-renal organ and/or islet
* Recipient of previous non-renal solid organ and/or islet cell transplantation
* Infection with hepatitis C virus (HCV) or human immunodeficiency virus (HIV)
* Inability or unwillingness of a participant to give written informed consent or comply with study protocol
* Any condition that, in the opinion of the investigator, would interfere with the participant's ability to comply with study requirements.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No